Peter Kirkpatrick - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Peter Kirkpatrick's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Peter Kirkpatrick
Verified
Chief Editor, Nature Reviews Drug Discovery
Beats
healthimmigration psychology
Lifestyle, Fashion, and Politics.
Content
By Peter Kirkpatrick Verified| Nature Verified Fifteen years ago, obesity drug development was out of favor, weighed down by limited efficacy and problems with side effects. But as recent clinical trials have shown strong weight-loss effects of glucagon-like peptide 1 (GLP-1) receptor agonists that were originally developed for type 2 diabetes, the field has ignited.
By Peter Kirkpatrick Verified| Nature Verified Last year was an outstanding period for deals focused on antibody–drug conjugates (ADCs), with Pfizer’s $43 billion acquisition of Seagen and AbbVie’s $10.1 billion buyout of ImmunoGen being among the highlights1. The popularity of the ADC platform has persisted in 2024, leading to several acquisitions and licensing deals with potential values in the billion-dollar range (as detailed in the deal snapshots).
By Peter Kirkpatrick Verified| Nature Verified Fifteen years ago, obesity drug development was out of favor, weighed down by limited efficacy and problems with side effects. But as recent clinical trials have shown strong weight-loss effects of glucagon-like peptide 1 (GLP-1) receptor agonists that were originally developed for type 2 diabetes, the field has ignited.
Company Info
Nature Reviews Drug Discovery
London, England, United Kingdom
+44 20 7833 4000